Connect with us

Hi, what are you looking for?

Please enter CoinGecko Free Api Key to get this plugin works.

Investing News

Maduro, Venezuela, the Drug War—Best Policy Is to Legalize All Prohibited Drugs

Jeffrey Miron

At the risk of repeating myself:

Set aside the legal issues raised by the US removal of Venezuelan President Nicolas Maduro (but see here and here for perspectives that make sense to me);

And assume, as asserted by the Trump administration, that Maduro has been involved or complicit in the illegal drug trade, with adverse consequences for the United States, such as violence, corruption, and overdoses.

Under these—the best case—conditions, is removing Maduro a good policy?

Not even close.

Removing Maduro might shift underground drug markets from Venezuela to other countries, temporarily, but even that is unlikely. And any disruption of the Venezuelan black market will likely exacerbate the adverse impacts of underground markets.

The right policy is for the US to legalize all currently prohibited drugs. This will eliminate underground drug markets, which are the real reason for most adverse consequences typically attributed to drugs.

Cross-posted from Substack.

You May Also Like

Economy News

Stock Market News: UK Forecast and Technical Analysis Today, the UK stock market saw the FTSE 250 increase by 195 points (0.9%) to 21,628,...

Economy News

Stock Market News: UK Forecast and Technical Analysis Today, the UK stock market saw the FTSE 250 increase by 195 points (0.9%) to 21,628,...

Economy News

Stock Market News: UK Forecast and Technical Analysis Today, the UK stock market saw the FTSE 250 increase by 195 points (0.9%) to 21,628,...

Economy News

Stock Market News: UK Forecast and Technical Analysis Today, the UK stock market saw the FTSE 250 increase by 195 points (0.9%) to 21,628,...



Disclaimer: financehightech.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.